A study assessed the effectiveness of pneumococcal conjugate vaccines (PCV-10 and PCV-13) against invasive Streptococcus pneumoniae in Canada from 2011 to 2017, analyzing 9,166 isolates.
The study found a significant decrease in the prevalence of serotypes covered by both vaccines over time, with PCV-13 showing better coverage overall compared to PCV-10.
Particularly, PCV-13 was more effective against multidrug-resistant strains, covering 53.3% of these isolates versus 14.6% for PCV-10, highlighting its superiority in combating resistant infections.